Novo Has Big Plans for 2030. Should You Buy the Stock Now?

Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.

The Motley Fool • an hour ago

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving.

24/7 Wall Street • 7 hours ago

16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage

Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.

24/7 Wall Street • Oct 28, 2026

Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test

Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday.

Investors Business Daily • Oct 28, 2026

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.

Zacks Investment Research • Oct 27, 2026

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.

The Motley Fool • Oct 27, 2026

Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick

Eli Lilly and Company has decisively outpaced Novo Nordisk A/S in the GLP-1/obesity/T2D market, now commanding a $1.21T valuation. NVO's share price has retraced all post-Wegovy gains; revenue growth is stagnant, but management's reset and pipeline strategy prompt a Buy upgrade. LLY's pipeline, momentum, and manufacturing strength support continued dominance, with the potential to surpass $100B in annual revenues as early as next year.

Seeking Alpha • Oct 27, 2026

US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk

A US judge rejected on Monday Novo Nordisk's request to block Eli ‌Lilly from continuing advertisements for weight-loss drugs that the Danish drugmaker considered false and misleading, affecting markets with tens of billions of dollars of annual sales.

Reuters • Oct 26, 2026

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

The S&P 500 remains in a confirmed uptrend, yet a big slice of the market isn't along for the ride. Money keeps crowding into the same mega-cap leaders, and plenty of solid companies sit below their 50-day moving averages even as their earnings outlooks hold up.

MarketBeat • Oct 26, 2026

Earn 12-15% Potential Income: Monthly Options Series (Nov. 2026)

Selling options can generate 12-15% annual income but requires discipline, risk management, and due diligence. We will discuss how to formulate a sustainable and repeatable income strategy for options. The PUT list emphasizes high-momentum stocks, while the BUY-WRITE CALL list prioritizes high dividend safety and quality scores for risk mitigation.

Seeking Alpha • Oct 26, 2026